Full-year and Q4 2019 results

14 February 2020 07:00 GMT
 

Pascal Soriot, Chief Executive Officer, commenting on the results said:

“In the first full year of our return to growth, we made good progress in line with our strategy. Results from our new medicines and Emerging Markets accompanied positive news for patients, most recently including regulatory approvals of Enhertu in breast cancer and Calquence in leukaemia. Our collaborations also progressed at pace, including that with Daiichi Sankyo, while there were several regulatory approvals for new medicines in China at the end of the year, such as Lynparza in first-line ovarian cancer.

Driven by a strong team, 2020 is anticipated to be another year of progress for AstraZeneca. We are becoming a better-balanced business, both regionally and through our medicines. This transition is a further step towards improving operating leverage and cash generation. As we accelerate our commitments to achieving our long- term climate-change and decarbonisation targets, we will maintain our focus on executing a strategy centred on science and patients.”
 


Adrian Kemp
Company Secretary
AstraZeneca PLC

Related:  Brilinta met primary endpoint in Phase III THALES trial in stroke

See More News From: